Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Glycobiology, Hematology, Xenotransplantation, and Ganglioside Pathway Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for B4GALNT2 drug discovery and genetic engineering. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | B4GALNT2 Recombinant Protein (Catalytic Domain, residues 74-520) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View B4GALNT2 Products |
| Gene Delivery | B4GALNT2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines preserving Golgi topology. |
View B4GALNT2 Products |
| Benchmark Ab | Anti-B4GALNT2 Recombinant Monoclonal Antibody Sequence-verified positive control for expression profiling and western blotting. |
View B4GALNT2 Products |
| Validator | B4GALNT2 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View B4GALNT2 Products |
| Related Target A | GGTA1 Critical synergistic target for triple-knockout (TKO) xenotransplantation models. |
View GGTA1 Products |
| Related Target B | CMAH Co-targeted for immunogenicity reduction in tissue engineering. |
View CMAH Products |
| Related Target C | VWF Downstream pathway target; B4GALNT2 regulates von Willebrand factor clearance. |
View VWF Products |
| Related Target D | ST3GAL1 Generates α2,3-sialylated acceptor substrates required for B4GALNT2 enzymatic activity. |
View ST3GAL1 Products |
| Related Target E | B4GALNT1 Homologous GM2 synthase; critical for selectivity counter-screening to avoid ganglioside pathway disruption. |
View B4GALNT1 Products |
| Related Target F | ST8SIA1 (GD3 Synthase) Downstream ganglioside pathway enzyme; co-target for GD2 modulation. |
View ST8SIA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic functional validation | Properly folded, HEK293 Expressed (Native Glycosylation) catalytic domains with strict purity control. |
| Subfamily counter screening | Homolog panel proteins (other GALNT family members) strictly verified by mass spec. |
| Lack of Robust Controls | Sequence-verified Recombinant Benchmark Antibodies included for reliable standard curves. |
| False Positives in Knockout studies | Validated siRNA sets included for robust specificity checks and baseline establishment. |
| Golgi Topology & Native Folding | HEK293-expressed Catalytic Domain with native glycosylation and theoretical MW. |
| Cross-species Preclinical Evaluation | Human / Mouse / Cyno ortholog proteins available with >95% purity. |
| Homolog Selectivity (B4GALNT1 Off-target) | Homolog panel proteins strictly verified by mass spec. |
| Cell-based Sda Antigen Detection | Lentivirus for stable, high-expression cell lines with Golgi-localized topology. |
Live B4GALNT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The strategic relevance of B4GALNT2 is expanding rapidly across three distinct therapeutic axes: xenotransplantation, cardiovascular/hematological regulation, and oncology. As a key glycosyltransferase responsible for synthesizing the Sd(a) blood group antigen, its modulation is critical. Major gene-editing companies are intensively targeting B4GALNT2 alongside GGTA1 and CMAH to generate organs devoid of xenoantigens, mitigating hyperacute rejection. Concurrently, new pharmacological research highlights its role in regulating von Willebrand factor (VWF) half-life, opening novel avenues for bleeding and thrombotic disorders. In oncology, B4GALNT2 is implicated in GM2/GD2 synthesis in neuroblastoma and melanoma, and its expression is linked to stemness and metastasis in gastrointestinal cancers. As next-generation therapies advance, the next wave of R&D will heavily feature precision modulation of the glycome through targeted inhibitors, CRISPR-Cas9 strategies, and isoform-selective approaches that spare B4GALNT1 activity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Editing (CRISPR/TALEN) | eGenesis, Revivicor, Makana Therapeutics | Xenotransplantation (Organ Rejection) | Knockout Validation (Need specific sequence-verified Abs and siRNAs) |
| Small Molecule Inhibitor | Preclinical academic labs, Rare disease biotechs | Thrombosis / VWF Regulation, Neuroblastoma, Melanoma | Enzymatic Selectivity Assay (Need high-purity catalytic domains) |
| Targeted Biomarkers | Oncology diagnostics developers | Gastrointestinal Cancers | Expression Profiling (Need HEK293 Expressed native antigens) |
| Anti-Adhesion Decoy | Glycobiology Research Consortia | Infectious Disease (Recurrent UTI) | Sda Antigen Binding Assay (Need ECD-Fc) |
| Anti-Sda mAb | Oncology Biotechs | Colorectal Cancer | Glycoform-specific Detection (Need cell lines) |
| siRNA/ASO | RNA therapeutics specialists | Neurodegeneration (Gangliosidoses) | Knockdown Efficiency Verification (Need validated siRNA) |
Key Mutations and Genetic Variants
Based on UniProt Q8NHY0, the following mutations are documented:
- rs7207403: A variant in dbSNP (UniProt VAR_049238) with potential functional implications.
- Sd(a-) phenotype variant: Found in individuals with the Sd(a-) phenotype; no effect on Sd(a) epitope biosynthesis (UniProt VAR_086499).
- Somatic mutation in colorectal cancer: Identified in a colorectal cancer sample; dbSNP:rs2042934144 (UniProt VAR_035990).
These mutations underscore the importance of sequence-verified reagents for accurate genotyping and functional studies.
Technical Specifications and Assay Strategy
Key Differentiation Factors
- Activity & Native Conformation: B4GALNT2 is a Golgi-resident glycosyltransferase. For small molecule inhibitor development, the enzyme must be highly pure and correctly folded for high-throughput UDP-GalNAc transfer assays. Bacterial expression often yields inactive inclusion bodies; HEK293 expression ensures native glycosylation and activity.
- Isoform Selectivity: B4GALNT2 shares ~45% sequence homology with B4GALNT1 (GM2 synthase). Best-in-class drugs require >100-fold selectivity over B4GALNT1 to avoid ganglioside pathway disruption and neurotoxicity.
- Subcellular Localization: The catalytic domain resides in the Golgi lumen. Small molecules must cross the Golgi membrane or access the active site during ER-Golgi transport, requiring appropriate pH stability (Golgi pH ~6.0-6.5).
- Safety & Off-target Control: The primary safety risk is off-target inhibition of B4GALNT1, leading to GM2 ganglioside deficiency. Early selectivity screening is essential.
Recommended Assays
- In vitro Enzymatic Kinetics: Use high-purity B4GALNT2 catalytic domain to evaluate inhibitor IC50 and binding affinity (e.g., fluorescence- or mass spectrometry-based transferase assays).
- Paralog Selectivity Screening: Provide strictly purified B4GALNT2 and B4GALNT1 proteins (both sequence-verified by mass spec) for cross-reactivity testing.
- Cell-based GM2 Generation Inhibition: Use lentivirus-transduced cells (e.g., HEK293 or SH-SY5Y) expressing full-length B4GALNT2 to measure GM2 levels by flow cytometry or immunofluorescence.
- Endogenous Expression Validation: Use validated siRNA sets (3 independent sequences, >80% knockdown) to confirm antibody specificity in Western blot or IHC.
TarMart Product Standards
- Sequence Accuracy: Catalytic domain covers UniProt Q8NHY0 residues 74-520, N-terminal 6xHis tag, sequence verified.
- Glycosylation: HEK293 expression ensures native glycosylation pattern, critical for stability.
- Endotoxin: <1 EU/µg (cell culture grade).
- Purity: >95% monomer by SEC-HPLC, theoretical MW ~65 kDa (SDS-PAGE verified).